Focus On Lyme executive director to speak at Capitol Hill science forum. Arizona-based group advocates for a definitive test for Lyme disease being developed by TGenContinue reading
Learn more about the bills AZBio is tracking at the Arizona Legislature
The FDA approved the first biosimilar in the U.S. in March of 2015 with more expected to be approved in 2016. Now, on a state by state basis, the laws that govern how these new therapies can be dispensed are being updated. Arizona has the opportunity to do so in 2016 with HB 2310 sponsored by Dr. Regina Cobb, Vice Chairman of the House Health Committee.Continue reading
Medical device innovators got good news on December 18th as Congress passed a two-year moratorium on a tax the industry said was limiting its growth. Companies and industry backers in Arizona and around the country have worked for years to repeal the 2.3 percent tax on revenue from medical device sales. Continue reading
THE WEEK THAT WAS
|BIO Actions & Activities|
Steve Ubl, president and CEO of AdvaMed will leave his post at AdvaMed in the fall to serve as president and CEO of PhRMA.
Ubl shared the letter below with the AdvaMed Board of Directors on Friday, September 25, 2015.Continue reading
21st Century Cures passes unanimously out of the House Energy and Commerce Committee.
“AZBio congratulates Members of the House Energy and Commerce Committee and all of the representatives of industry, patients, and our key federal agency partners on a truly collaborative effort to progress H.R. 6 – The 21st Century Cures Act.” Joan Koerber-Walker, President & CEO, Arizona Bioindustry Association (AZBio) and Chair, AdvaMed State Medical Technology Alliance Continue reading
While AZBio and its members recognize that the State of Arizona and the legislature must work diligently to balance the State Budget – which includes implementation of SB1475 and a 5% rate cut to providers of healthcare services – the end result may ultimately increase the state’s healthcare spend rather than reduce it.Continue reading
The success of the Jumpstart Our Business Startups (JOBS) Act in the biotech industry means that the work of the Subcommittee on Capital Markets and Government Sponsored Enterprises has taken on increased importance for emerging biotech companies. Current bills being considered could help to further support the search for breakthrough treatments at the next generation of emerging growth biotech companies.Continue reading